Comparative Pharmacology
Head-to-head clinical analysis: GRISEOFULVIN ULTRAMICROSIZE versus LYNOZYFIC.
Peer-Reviewed Evidence
Head-to-head clinical analysis: GRISEOFULVIN ULTRAMICROSIZE versus LYNOZYFIC.
GRISEOFULVIN, ULTRAMICROSIZE vs LYNOZYFIC
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Binds to tubulin, disrupting microtubule function and inhibiting fungal cell mitosis; deposited in keratin precursor cells, making keratin resistant to fungal invasion.
Selective serotonin reuptake inhibitor (SSRI); inhibits serotonin transporter (SERT) in the presynaptic terminal, increasing synaptic serotonin levels.
250-375 mg orally once daily or 500-750 mg orally once daily for severe infections.
1000 mg intravenously every 12 hours infused over 2 hours
None Documented
None Documented
9-24 hours (mean 15 hours); prolonged in liver disease.
Terminal elimination half-life is 12.4 hours (range 11.2–14.1 hours) in patients with normal renal function; allows twice-daily dosing for steady-state within 3 days.
Renal (<1% unchanged); fecal (36% as metabolites); tissue deposition may persist for weeks.
Renal excretion of unchanged drug accounts for approximately 65% of elimination; biliary/fecal excretion accounts for 25%; the remaining 10% is metabolized by hepatic CYP3A4-mediated oxidation.
Category D/X
Category C
Antifungal
Antifungal